Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

@article{Lacouture2011PresenceOF,
  title={Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.},
  author={Mario E. Lacouture and Paul B Chapman and Antoni Ribas and Jeffrey A. Sosman and Grant Mcarthur and Keith T. Flaherty and Kevin B Kim and Igor J. Puzanov and Keith B. Nolop and Andrew K. Joe and Olivia Spleiss and Astrid Koehler and William C H Wu and Caroline Robert and A. H. W. Hauschild and Dirk Schadendorf and James L. Troy and Madeleine Duvic and Kerstin Trunzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={8520}
}
8520 Background: Vemurafenib (V; RG7204, PLX4032), an oral inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety, efficacy, and pharmacokinetics in dose escalation and melanoma extension cohorts from the Phase I study (n=87; Flaherty, et al. NEJM, 2010). Development of cuSCC/KA was observed in melanoma patients (pts). Here we describe further molecular characterization of confirmed cases of cuSCC/KA. METHODS Pts receiving V therapy were monitored for toxicity including… CONTINUE READING